POPULARITY
Categories
71 episodes with inhibitors
45 episodes with inhibitors
58 episodes with inhibitors
58 episodes with inhibitors
52 episodes with inhibitors
52 episodes with inhibitors
70 episodes with inhibitors
32 episodes with inhibitors
24 episodes with inhibitors
29 episodes with inhibitors
53 episodes with inhibitors
22 episodes with inhibitors
24 episodes with inhibitors
16 episodes with inhibitors
22 episodes with inhibitors
11 episodes with inhibitors
29 episodes with inhibitors
25 episodes with inhibitors
27 episodes with inhibitors
15 episodes with inhibitors
27 episodes with inhibitors
12 episodes with inhibitors
18 episodes with inhibitors
12 episodes with inhibitors
10 episodes with inhibitors
16 episodes with inhibitors
26 episodes with inhibitors
21 episodes with inhibitors
13 episodes with inhibitors
29 episodes with inhibitors
22 episodes with inhibitors
17 episodes with inhibitors
10 episodes with inhibitors
10 episodes with inhibitors
12 episodes with inhibitors
13 episodes with inhibitors
8 episodes with inhibitors
7 episodes with inhibitors
8 episodes with inhibitors
6 episodes with inhibitors
7 episodes with inhibitors
6 episodes with inhibitors
13 episodes with inhibitors
25 episodes with inhibitors
6 episodes with inhibitors
3 episodes with inhibitors
5 episodes with inhibitors
8 episodes with inhibitors
8 episodes with inhibitors
8 episodes with inhibitors
6 episodes with inhibitors
4 episodes with inhibitors
6 episodes with inhibitors
4 episodes with inhibitors
Featuring perspectives from Dr Farrukh T Awan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, moderated by Dr Kahl, including the following topics: Introduction: Biology of Non-Hodgkin Lymphoma (NHL) (00:00) Current Role of CD20 x CD3 Bispecific Antibodies in NHL (4:49) Role of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma (DLBCL) (27:48) Optimal Application of Loncastuximab Tesirine for Patients with DLBCL and Follicular Lymphoma (41:43) Role of Bruton Tyrosine Kinase (BTK) Inhibitors Alone or with Anti-CD20 Antibodies for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) (1:00:43) Combining BTK Inhibitors with Bcl-2 Inhibitors (1:31:15) Current and Future Role of Noncovalent BTK Inhibitors in CLL (1:41:30) CME information and select publications
Dr. Niyati A. Borkar speaks with Dr. Yaping Tu and Dr. Thomas B. Casale about their article, "Pirfenidone and its Derivative: Novel Bronchodilators and Leukocyte Airway Inflammation Inhibitors."
This article is for educational purposes only and is not a substitute for individualized medical advice. Always talk to your own healthcare provider before changing your diet, supplements, or medications.Unlocking the Secrets of Ferritin: What Your Iron Levels Are Telling YouYour “normal” bloodwork might be hiding the real reason you're exhausted, foggy, and losing hairTL;DR: * Ferritin is your iron savings account — and most labs only flag it as “abnormal” once it's nearly empty. * A level of 14 or 22 ng/mL might get a “you're fine” from your doctor, but optimal energy, mood, cognition, and hair growth usually need ferritin closer to 70–100 ng/mL. * Low ferritin can come from menstrual blood loss, poor absorption (celiac disease, low stomach acid, H. pylori), or inflammation-driven hepcidin blocking iron uptake.* If you're fatigued, foggy, cold, or shedding hair, ask for a full iron panel — not just a ferritin number — and talk through the results with your doctor.There's an old Japanese proverb: “When the body speaks, the wise person listens. When the body whispers, the fool waits for it to scream.” In health diagnostics, one of the quietest whispers is your ferritin level. It's often overlooked, yet it can be the missing link behind exhaustion, hair loss, brain fog, or the frustrating experience of bloodwork that comes back “normal” while you still feel terrible.What Is Ferritin?Ferritin is your body's iron storage protein. Think of your iron levels like a financial setup: hemoglobin is your checking account, drawn on daily. Ferritin is your savings account, tapped only when things get tight. Under stress, your body will drain the savings account long before it lets the checking account — hemoglobin — run low. That's why you can have “normal” hemoglobin and still be iron-depleted. A low ferritin level means your reserves are running out, and that shows up as fatigue, brain fog, mood changes, and thinning hair.Normal vs. OptimalMost labs flag ferritin as “normal” above roughly 10–20 ng/mL. That threshold mostly means you're not in immediate danger — not that you're thriving. Levels associated with feeling genuinely well tend to run from 70 to 100 ng/mL. So if you've been told your ferritin of 14 or 22 is fine, but you still feel wiped out, you're not imagining it — you're just being measured against a bar set for avoiding crisis, not for feeling good.Why Your Ferritin Might Be Low* Menstrual blood loss. For many women, the cumulative loss over months and years outpaces dietary iron intake, slowly draining reserves.* Absorption issues. Even a solid iron intake doesn't help if it isn't absorbed. Silent celiac disease, low stomach acid, or an H. pylori infection can quietly block uptake for years.* Inhibitors and hepcidin. Coffee, tea, and dairy consumed close to meals can inhibit iron absorption. Separately, inflammation can push your liver to produce hepcidin, a hormone that shuts down iron uptake even when you're eating enough.Symptoms to WatchPersistent fatigue, thinning hair, feeling cold more easily than others, and brain fog are the classic signs. If two or more of these sound familiar, it's worth getting your ferritin checked specifically — not just assumed to be fine because your CBC looked normal.The Bigger PictureIron does far more than carry oxygen. It's involved in thyroid hormone conversion, dopamine production, mitochondrial energy synthesis, and hair follicle health. That means low ferritin can produce symptoms that look a lot like depression or hypothyroidism — even when your thyroid panel and mood screening come back clean.Taking Action* Review your bloodwork. Look specifically at ferritin. Anything under 70 ng/mL is worth a conversation with your doctor.* Ask for a full iron panel. Ferritin alone isn't the whole story — request serum iron, total iron binding capacity (TIBC), transferrin saturation, and CRP (to rule out inflammation skewing the picture).* Adjust absorption habits. Space coffee and tea away from meals, lean into iron-rich foods, and avoid taking calcium and iron supplements together.* Choose the right supplement, if needed. Ferrous sulfate is harsh on the gut for many people. Iron bisglycinate is gentler and pairs well with vitamin C for better absorption — but check with your provider before starting, especially if high ferritin is a concern.* Loop in a professional. This is especially important before making changes if you suspect elevated ferritin, since iron overload carries its own risks.Listening to Your Body's WhisperYour body is constantly sending signals. Ignored long enough, whispers become screams. Taking ferritin seriously — not just as a checkbox on a lab report, but as a meaningful marker — is one concrete way to catch a problem while it's still easy to fix.Final ThoughtsMonitoring and optimizing ferritin can meaningfully change how you feel day to day. It starts with a simple ask: get the right test, read the number in context, and act on what it's telling you. If you want a more personalized look at your own levels and symptoms, consider scheduling a comprehensive health session.Stay informed, stay healthy, and listen closely to what your body is telling you. Until next time, take care.References* Camaschella, C. (2015). Iron-deficiency anemia. New England Journal of Medicine.* WHO guidance on serum ferritin concentrations for the assessment of iron status.* Clinical literature on ferritin thresholds and symptomatic iron deficiency without anemia.* Hepcidin and inflammation's role in iron regulation — recent reviews in Blood and Haematologica. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit tripleplaydoc.substack.com/subscribe
Access Transcript | Access Slides | Obtain Credit | For More Information …
Featuring perspectives from Dr Harold J Burstein and Dr Joyce O'Shaughnessy, including the following topics: Introduction: ODAC — April 30, 2026 (00:00) Adjuvant CDK4/6 Inhibitors (13:03) Adjuvant Oral Selective Estrogen Receptor Degraders (21:53) Premenopausal Patients (30:52) Duration of Adjuvant Endocrine Treatment (38:44) Genomic Predictors of Chemotherapy Benefit (47:19) Neoadjuvant Treatment (55:13) CME information and select publications
In this episode, we review the high-yield topic of Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) from the Psychiatry section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HPB865. CME/MOC/AAPA/IPCE credit will be available until June 28, 2027.Partnering Up to Facilitate Change in TGCT Care: Team-Based Tactics for Integrating Modern CSF1R Inhibitors in Clinical Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from EMD Serono, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HPB865. CME/MOC/AAPA/IPCE credit will be available until June 28, 2027.Partnering Up to Facilitate Change in TGCT Care: Team-Based Tactics for Integrating Modern CSF1R Inhibitors in Clinical Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from EMD Serono, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HPB865. CME/MOC/AAPA/IPCE credit will be available until June 28, 2027.Partnering Up to Facilitate Change in TGCT Care: Team-Based Tactics for Integrating Modern CSF1R Inhibitors in Clinical Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from EMD Serono, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HPB865. CME/MOC/AAPA/IPCE credit will be available until June 28, 2027.Partnering Up to Facilitate Change in TGCT Care: Team-Based Tactics for Integrating Modern CSF1R Inhibitors in Clinical Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from EMD Serono, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TJT865. CME/AAPA/IPCE credit will be available until June 16, 2027.Building Strong Communities of Care in NF1: Collaborative Strategies and Management Choices With MEK Inhibitors for NF1-PNs Across Age Groups In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Neurofibromatosis Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Alexion, AstraZeneca Rare Disease and SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TJT865. CME/AAPA/IPCE credit will be available until June 16, 2027.Building Strong Communities of Care in NF1: Collaborative Strategies and Management Choices With MEK Inhibitors for NF1-PNs Across Age Groups In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Neurofibromatosis Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Alexion, AstraZeneca Rare Disease and SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TJT865. CME/AAPA/IPCE credit will be available until June 16, 2027.Building Strong Communities of Care in NF1: Collaborative Strategies and Management Choices With MEK Inhibitors for NF1-PNs Across Age Groups In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Neurofibromatosis Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Alexion, AstraZeneca Rare Disease and SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TJT865. CME/AAPA/IPCE credit will be available until June 16, 2027.Building Strong Communities of Care in NF1: Collaborative Strategies and Management Choices With MEK Inhibitors for NF1-PNs Across Age Groups In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Neurofibromatosis Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Alexion, AstraZeneca Rare Disease and SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.
Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on SGLT2 Inhibitors in Cardio-Oncology: A Systematic Review and Meta-Analysis.
Real Life Pharmacology - Pharmacology Education for Health Care Professionals
In this episode, we explore monoamine oxidase inhibitors (MAOIs), one of the oldest yet most effective classes of antidepressants. We discuss how MAOIs such as phenelzine, tranylcypromine, isocarboxazid, and selegiline work by increasing serotonin, norepinephrine, and dopamine levels in the brain. The episode reviews their unique role in treatment-resistant and atypical depression, key adverse effects, important dietary considerations involving tyramine-containing foods, and potentially serious drug interactions. We also highlight practical clinical pearls to help pharmacists and healthcare professionals safely and effectively use these powerful but often underutilized medications. Be sure to check out our free Top 200 study guide – a 31 page PDF that is yours for FREE! Support The Podcast and Check Out These Amazing Resources! NAPLEX Study Materials BCPS Study Materials BCACP Study Materials BCGP Study Materials BCMTMS Study Materials Meded101 Guide to Nursing Pharmacology (Amazon Highly Rated) Guide to Drug Food Interactions (Amazon Best Seller) Pharmacy Technician Study Guide by Meded101
Treatment options for eczema have come a long way, with many new non-steroidal choices. One type is the JAK inhibitor, which offers two things people have long wanted: a non-steroidal option and a more advanced option that, unlike a biologic, does not require injection. Kortney and Dr. Payel Gupta sit down with returning guest Dr. Nicole Chase, to break down what a JAK inhibitor actually is, how the pill and cream versions differ, how JAK inhibitors compare to biologics, and what to know about safety. They also cover what is new, including a topical JAK now approved for children as young as two. What we cover in this episode about JAK inhibitors for eczema What eczema really is. How JAK inhibitors work. Pills versus creams. JAK inhibitors versus biologics. Safety and side effects. Made in partnership with The Allergy & Asthma Network. Thanks to Incyte for sponsoring today's episode. This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.
Which patients with Alagille syndrome benefit from IBAT inhibitors, and what should you watch for during therapy? Credit available for this activity expires: 6/16/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/navigating-management-alagille-syndrome-using-ileal-bile-2026a1000g3c?ecd=bdc_podcast_libsyn_mscpedu
Drs. Benjamin Catanese and Daniel Edmonston discuss their study, "Cardiovascular Outcomes among New Users of GLP-1 Receptor Agonists Compared with DPP-4 Inhibitors and Sulfonylureas in Kidney Failure," with JASN Deputy Editor Manjula Kurella Tamura.
Summary: Hidradenitis Suppurativa (HS) is one of dermatology's most complex and underrecognized conditions and the treatment landscape is changing fast. In this episode, Dr. Faranak Kamangar sits down with Dr. Hadar Lev-tov, Associate Professor at the University of Miami, Director of the Wound Healing Fellowship, and Immediate Past President of the Hidradenitis Suppurativa Foundation, for a rapid-fire review of everything happening in the HS world right now. Dr. Lev-tov covers the currently approved therapies, the exciting drugs moving through Phase 3 trials, and the groundbreaking science linking microplastics to HS inflammation. He also shares his candid take on GLP-1s in HS management and what the future of dermatology looks like when treatments work so well that doctors can finally focus on the whole patient. Whether you're a resident just learning HS or a seasoned dermatologist trying to keep up with a fire-hose pipeline, this one is for you. Topics Covered: - Approved HS biologics: bimekizumab, secukinumab, adalimumab & biosimilars - Off-label use of infliximab (IV and subcutaneous) in severe HS - Phase 3 pipeline: remibrutinib, povorcitinib, sonelokimab (nanobodies) - CAR T-cell therapy and the possibility of curing inflammatory skin disease - Microplastics, nicastrin, and a landmark Nature Communications paper on HS - GLP-1s in HS: what we know, what we don't, and Dr. Levtov's clinical approach - The HS Foundation's research grants, HS Academy, wound care referral tool, and prior authorization templates - The future of dermatology as lifestyle medicine Resources Mentioned: - https://www.nature.com/articles/s41467-025-65789-7 - HS Foundation website & prior authorization templates: https://www.hs-foundation.org/ - HS Academy (free weekend for residents): https://www.hs-foundation.org/hs-academy - Integrative Dermatology Symposium: integrativedermatologysymposium.com - LearnSkin: learnskin.com This podcast is for educational purposes only and is not a substitute for professional medical advice. Always consult your healthcare provider. Key Takeaways: 1. Validate HS patients the moment they walk in. They've often been dismissed or bounced between providers for years. Simply saying "I understand what you're going through" builds trust immediately and makes the visit more productive. 2. The approved HS treatment arsenal is growing. Bimekizumab and secukinumab (IL-17 inhibitors) are now approved, and adalimumab — including biosimilars — remains a valuable option. Clinical experts are using biosimilars with confidence. 3. Subcutaneous infliximab is an emerging option. Available off-label in the US, new data from French centers shows a protocol: standard IV induction at weeks 0, 2, and 6, then switching to subcutaneous injections every two weeks at week 10 — but only once the patient is in strong remission. 4. Three major drugs are in or completing Phase 3 trials. Remibrutinib (BTK inhibitor, already approved for chronic spontaneous urticaria), povorcitinib (JAK1 inhibitor), and sonelokimab (a nanobody targeting IL-17A and IL-17F) are all reporting promising results and moving toward FDA application. 5. Nanobodies are a technology to watch. Derived from camelid antibody fragments, nanobodies like sonelokimab can be engineered to target multiple pathways simultaneously in a smaller, more modular molecule — expect to see them across dermatology. 6. Half-life extenders could mean one injection per year. Already emerging in psoriasis, these extended-dosing biologics are heading toward HS — a potential game-changer for patient adherence. 7. CAR T-cell therapy may one day cure inflammatory skin disease. Currently being studied in lupus and rheumatoid arthritis, the protocols are becoming more practical, and the technology is edging toward dermatology. 8. Microplastics may potentiate HS inflammation. A Nature Communications paper by Dr. Luis Garza (Hopkins) found that plastic-associated endocrine disruptors block nicastrin in fibroblasts, amplifying HS-related inflammation. This doesn't prove causation, but it reveals a meaningful environmental link — and highlights the underappreciated role of fibroblasts in HS scarring. 9. GLP-1s in HS: promising but not proven as monotherapy. There's no RCT yet. Dr. Levtov's clinical approach: stabilize HS with a biologic first, then consider adding a GLP-1 as part of a comprehensive plan that includes diet and resistance training. He has seen outcomes go both ways. 10. The HS Foundation is an underutilized resource. Their website offers a clinic finder, wound care referral service, prior authorization templates (one-click Word documents), research grants, the HS Academy (free, all-expenses-paid weekend for residents), and career development awards in partnership with the Dermatology Foundation. Chapters: 0:00 – Introduction & Dr. Lev-tov's Background 0:49 – The #1 Clinical Tip for Seeing HS Patients 1:44 – Approved HS Treatments: IL-17 Inhibitors, Adalimumab & Biosimilars 2:40 – Off-Label Infliximab: IV and the New Subcutaneous Protocol 4:21 – Phase 3 Pipeline: Remibrutinib, Povorcitinib & Sonelokimab (Nanobodies) 6:00 – Half-Life Extenders & One-Injection-Per-Year Future 7:01 – CAR T-Cell Therapy: Could We Cure Inflammatory Skin Disease? 7:36 – Research Funding & HS Foundation Grants 8:43 – HS Foundation Tools: Prior Auth Templates, Clinic Finder & HS Academy 10:15 – Microplastics, Nicastrin & the Nature Communications Paper 13:22 – What This Means for Fibroblasts and HS Scarring 14:20 – Celebrating Dermatology Science & Clinician-Scientists 15:32 – GLP-1s & HS: What's the Evidence? 17:18 – Dr. Lev-tov's Clinical Approach to GLP-1 Requests 19:06 – The Future of Dermatology: Becoming Lifestyle Doctors 21:28 – The Integrative Dermatology Symposium & LearnSkin Certificate Program 22:50 – Closing Remarks
Sickle cell disease causes accelerated kidney function decline, yet proven GFR-preserving therapies remain elusive. In this study of adults with sickle cell disease, RASi use was not associated with a significant difference in the rate of eGFR decline.
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia | Faculty Presentation 2: Emerging BTK Inhibitor-Based Combination Approaches in CLL — Jennifer R Brown MD, PhD CME information and select publications
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia | Faculty Presentation 1: Role of Bruton Tyrosine Kinase (BTK) Inhibitors in Newly Diagnosed and Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) — Wojciech Jurczak MD, PhD CME information and select publications
Proceedings from a webinar on March 11, 2026, moderated by Dr Neil Love, including the following topics: Introduction: I think I missed that day in med school (BTK biology) (0:00) First-Line Treatment (11:40) Relapsed/Refractory Disease (46:35) CME information and select publications
In this episode of the Oncology Brothers podcast, we dived deep into the world of BRAF V600E-mutated non-small cell lung cancer treatment options. Joined by Dr. Melissa Johnson, a thoracic medical oncologist and director of lung cancer research at the Sarah Cannon Research Institute, the discussion focused on two critical BRAF and MEK inhibitor combinations: Dabrafenib plus Trametinib and Encorafenib plus Binimetinib. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Key topics included: Overview of the efficacy and survival data for both combinations Side effect profiles and management strategies Clinical pearls for oncologists in practice The importance of NGS testing in smokers and the role of targeted therapy versus chemoimmunotherapy Join us as we explore the latest insights and recommendations for managing these therapies, ensuring better patient outcomes and quality of life. Don't forget to check out our previous episodes for more on treatment algorithms and conference highlights! #BRAFmutation, #NSCLC, #BRAF-MEK-inhibitor, #TargetedTherapy, #OncologyBrothers
Keeping patients on PARP inhibitors long enough to see real benefit often comes down to proactive side effect management. In this episode of BackTable Urology, Dr. Neeraj Agarwal and Dr. Arun Azad join host Dr. Alan Tan to discuss practical, evidence-based strategies for managing hematologic and GI toxicities in advanced prostate cancer patients receiving PARP inhibitors. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Pfizer. --- Timestamps 00:00 - Introduction06:17 - Managing Anemia11:12 - Side Effect Profiles19:33 - Transfusions vs ESAs26:43 - Docetaxel vs PARP Inhibitors30:27 - Side Effect Management Pearls40:18 - Team Based Monitoring52:27 - Tissue Versus Liquid01:01:24 - Genetic Counseling Workflow01:07:07 - Trial Equity and Access --- More about this episode The doctors discuss the importance of close anemia monitoring during the critical first 3 to 4 months of therapy, maintaining dose intensity, proactive antiemetic use, and the role of exercise and resistance training in combating fatigue. The conversation also covers differences in toxicity profiles between PARP agents, the value of multidisciplinary care teams, molecular advances in molecular and germline testing, and the evolving landscape of emerging therapies in prostate care. --- Resources Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trialhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00684-1/abstract BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm).https://ascopubs.org/doi/10.1200/JCO.2024.42.4_suppl.19 --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app
Featuring a slide presentation and related discussion from Dr Wassim Abida, including the following topics: Clinical implications of homologous recombination repair gene alterations and biological rationale for the use of PARP inhibitors (0:00) Key clinical studies leading to FDA approvals of PARP inhibitors as monotherapy (5:01) Biological rationale for combining PARP inhibitors with androgen receptor pathway inhibitors and key findings from the Phase III PROpel study (11:03) Key findings from the Phase III MAGNITUDE and TALAPRO-2 studies (15:10) Summary of efficacy data with PARP inhibitors; toxicities (20:01) Key findings and conclusions from the Phase III AMPLITUDE study; future directions with PARP inhibitors (23:33) CME information and select publications
Featuring an interview with Dr Wassim Abida, including the following topics: Comparing the clinical relevance of BRCA1 and BRCA2 mutations in prostate cancer (0:00) Relevance and interpretation of LOH (loss of heterozygosity) scores (4:37) Incidence and clinical relevance of PALB2 mutations; role of genetic counseling in the care of patients with prostate cancer (9:33) Key considerations surrounding toxicities associated with PARP inhibitors (15:25) Potential role of saruparib; evolving nomenclature in prostate cancer (22:36) Approach to newly diagnosed metastatic prostate cancer (26:16) Clinical relevance of PSMA-targeted PET imaging results (29:49) Case: A man in his mid 70s with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious BRCA alteration receives olaparib/abiraterone/prednisone upon relapse (32:15) Combining PARP inhibitors with other DNA repair inhibitors; insights on the PSMAddition trial (37:14) Case: A man in his mid 60s with metastatic prostate adenocarcinoma and a BRCA germline mutation receives niraparib/abiraterone/prednisone (43:17) Case: A man in his early 60s with mCRPC and CDK12 mutations receives talazoparib/enzalutamide (45:54) CME information and select publications
Another incredible discovery inside the human body—our built-in recycling system and its surprising role in cholesterol control. What happens when that recycle bin works… or doesn't? Welcome to the fascinating world of the enzyme PCSK9.
In this episode of the Oncology Brothers podcast, we dived into the world of anti-EGFR therapies in non-small cell lung cancer (NSCLC). Joined by Dr. Joshua Sabari from NYU Langone Health and Dr. Azam Farooqui from Ironwood Cancer and Research Center, we discussed the latest advancements in treatment options, including the use of osimertinib, afatinib, and the combination therapy of amivantamab and lazertinib. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Key topics include: The role of afatinib in treating uncommon EGFR mutations and its associated toxicities The well-tolerated profile of osimertinib and its common side effects, including rash, diarrhea, and the rare risk of pneumonitis Insights into the combination therapy of amivantamab and lazertinib, including management of skin toxicity and the importance of prophylactic anticoagulation to mitigate VTE risks The episode emphasized the importance of maintaining quality of life for patients while ensuring they can stay on effective therapies for longer periods. Tune in for valuable clinical pearls and strategies to optimize patient care in the community setting. Don't forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms and conference highlights! #LungCancer, #NSCLC, #EGFR, #TargetedTherapy, #OncologyBrothers
Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice reviewModerator:Ursula A. Matulonis, MD; Dana-Farber Cancer InstituteSpeakers:Bhavana Pothuri, MD; Perlmutter Cancer Center, NYU Langone HealthRóisín E. O'Cearbhaill, MD; Gynecologic Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center; Department of Medicine, Weill Cornell Medical CollegeYvette Drew, MBBS, PhD; BC Cancer Centre Vancouver and University of British ColumbiaChristina Washington, MD; Stephenson Cancer Center, University of OklahomaUrsula A. Matulonis, MD, is joined by Bhavana Pothuri, MD, Róisín O'Cearbhaill, MD, Yvette Drew, MBBS, PhD, and Christina Washington, MD, to discuss recent updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors (PARPi) in ovarian cancer. Based on the recent Society of Gynecologic Oncology clinical practice review published in Gynecologic Oncology, the speakers review the evolving role of PARP inhibitors and the clinical implications of updated regulatory approvals.The panel explores current evidence supporting PARP inhibitor use in ovarian cancer, including considerations for patient selection, biomarker testing, maintenance therapy, and safety considerations. The speakers also discuss how recent changes in FDA indications may affect clinical decision-making and treatment sequencing in practice.This podcast highlights practical clinical pearls to help guide practitioners in the appropriate integration of PARP inhibitors into the management of ovarian cancer patients.This podcast was developed by the Society of Gynecologic Oncology for Gynecologic Oncology.Check out more content on the journal's homepage at https://www.gynecologiconcology-online.net
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/WNB865. CME/AAPA credit will be available until April 21, 2027.A New Era in Psoriasis Care With Oral IL-23 Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/WNB865. CME/AAPA credit will be available until April 21, 2027.A New Era in Psoriasis Care With Oral IL-23 Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/WNB865. CME/AAPA credit will be available until April 21, 2027.A New Era in Psoriasis Care With Oral IL-23 Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/WNB865. CME/AAPA credit will be available until April 21, 2027.A New Era in Psoriasis Care With Oral IL-23 Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/WNB865. CME/AAPA credit will be available until April 21, 2027.A New Era in Psoriasis Care With Oral IL-23 Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
Please visit answersincme.com/860/IME-018263-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by April W. Armstrong, MD, MPH and Lawrence J. Green, MD. In this activity, experts in psoriasis review the latest evidence on approved and emerging TYK2 inhibitors for patients with moderate to severe plaque psoriasis. Upon completion of this activity, participants should be better able to: Recognize unmet needs in the treatment of patients with moderate to severe plaque psoriasis; Differentiate TYK2 signaling from JAK pathways and their relevance to clinical practice; and Review clinical trial data on approved and emerging TYK2 inhibitors for patients with moderate to severe plaque psoriasis.
Drs. Maron and Rowin review how treatment for symptomatic obstructive hypertrophic cardiomyopathy has evolved from mainly using beta blockers and invasive procedures to now including newer cardiac myosin inhibitor drugs. These newer medications more reliably reduce obstruction and improve patient symptoms and exercise capacity, but require careful safety monitoring with regular heart function checks.
In this podcast, experts Naval G. Daver, MD; Amir Fathi, MD; Guillermo Garcia-Manero, MD; and Aditi Shastri, MD, discuss current applications for menin inhibitors in patients with acute leukemia, combination approaches under investigation, and managing treatment-related adverse events with menin inhibitors.
In this clinically rich episode, host Dr. Ted Lain sits down with board-certified dermatologist and global skin cancer expert Dr. Todd Schlesinger — AAD Board of Directors member, Mohs surgeon, clinical assistant professor at George Washington University School of Medicine, and medical director of the Clinical Research Center of the Carolinas — for a deep dive into systemic and targeted therapies for non-melanoma skin cancer (NMSC). The doctors begin with a thorough breakdown of the hedgehog signaling pathway (PATCHED, Smoothened, GLI-1 transcription) and how mutations in this pathway drive basal cell carcinoma (BCC) growth. They compare the two FDA-approved hedgehog pathway inhibitors (HHIs) — vismodegib (Erivedge) and sonidegib (Odomzo) — covering their mechanisms of action, volume of distribution differences (16–18L vs. ~9,000L), indications for locally advanced and metastatic BCC, how to define "locally advanced," and complete vs. partial response rates. Dosing strategies are addressed in detail, including alternate-day dosing and treatment breaks backed by the MIKIE study and STEVIE safety study. For managing the most common adverse events — muscle cramps, dysgeusia, weight loss, and fatigue — Dr. Schlesinger shares his clinical protocol using L-carnitine supplementation (1,500–2,000mg liquid, started 2–4 weeks before therapy) along with calcium and CoQ10. The conversation then moves to PD-1 and PD-L1 checkpoint inhibitors for locally advanced and metastatic cutaneous squamous cell carcinoma (cSCC) and BCC, covering cemiplimab (Libtayo), pembrolizumab (Keytruda), and nivolumab (Opdivo). The hosts explain the immune checkpoint mechanism using a memorable analogy, discuss how UV exposure upregulates PD-1 on tumor cells, and explore the practical realities of dermatologists prescribing infusion-based immunotherapy — including multidisciplinary care team logistics, buy-and-bill considerations, and when to partner with oncology. The episode closes with an exciting look at the pipeline: intralesional therapies for nodular and superficial BCC from companies including Verica, iViva, PHIO, and Feldan, red light PDT for superficial BCC nearing FDA approval, and the broader question of where these drugs fit as neoadjuvant, adjuvant, or primary therapies — and what complete response benchmarks (80–95%) dermatologists should expect before adopting non-surgical primary options. To watch this and other episodes, be sure to check out our YouTube page DISCLAIMER: This podcast is not intended to provide diagnosis, treatment, or medical advice. Content provided in this podcast is for educational purposes only. Please consult with a physician regarding any health-related diagnosis or treatment.See omnystudio.com/listener for privacy information.
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Menin Inhibitors in Acute Myeloid Leukemia | Faculty Presentation 2: Potential Role of Menin Inhibitors as a Component of Combination Therapy — Amir Fathi, MD CME information and select publications
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Menin Inhibitors in Acute Myeloid Leukemia | Faculty Presentation 1: Biology Underlying the Utility of Menin Inhibitors in Acute Leukemias: Use of These Agents as Monotherapy — Eunice S Wang, MD CME information and select publications
Featuring perspectives from Dr Amir Fathi and Dr Eunice S Wang, including the following topics: Introduction: Overview — Biopharmacologic Considerations (0:00) Menin Inhibitor Monotherapy (21:51) Differentiation Syndrome (36:12) Menin Inhibitor Combination Approaches (45:15) Future Directions (49:59) PARADIGM — Randomized Phase II Trial (53:24) CME information and select publications
In this episode, we review the high-yield topic of Monoamine Oxidase (MAO) Inhibitors from the Psychiatry section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
Send me a derm question or story!Allergy cases can be REALLY tough!In this week's podcast episode, we explore how veterinarians and staff can build confidence using the full range of allergy medications available. From JAK inhibitors to monoclonal antibodies to cyclosporine, I discuss the importance of knowing the mechanisms and clinical applications of these medications. Atopic dermatitis is a syndrome with many layers. You can have your favorite allergy drugs, but there will always be difficult cases that don't respond and we need to try something different.Tune in for practical insights, real-world case strategies, and tips to help you feel more comfortable navigating complex allergic conditions. Studies:https://pubmed.ncbi.nlm.nih.gov/34344611/https://pubmed.ncbi.nlm.nih.gov/20887404/Timestamps00:00 Intro00:44 New Segments Starting Soon02:07 Being Comfortable w/ Allergy Medications03:25 Breed-Specific Allergy Phenotypes05:07 JAK Inhibitors06:45 Monoclonal Antibodies08:36 Cyclosporine09:58 Summary12:41 Outro
Dr. Dacher Keltner, PhD, is a professor of psychology at the University of California, Berkeley, and a leading expert on the science of emotions and human connection. We discuss the science of awe—what evokes it and how to access it. Dr. Keltner explains how awe helps us frame our experience of life and who we are both as individuals and collectively. We also discuss the role of humor in social bonding, dispel common myths about the biology of emotions and review the lesser-known factors that strengthen or inhibit relationships and communities. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman Joovv: https://joovv.com/huberman Helix Sleep: https://helixsleep.com/huberman Function: https://functionhealth.com/huberman Our Place: https://fromourplace.com/huberman Timestamps (00:00:00) Dr Dachner Keltner (00:01:55) Emotions, Awe; Facial Expressions & Culture (00:08:11) Sponsors: Joovv & Helix Sleep (00:11:05) Emotion, Motor Movement & Language (00:15:36) Measuring Emotion; Studying Awe (00:24:10) Horizons, Small to Vast, Shifting Perspective (00:29:27) Tool: Awe Walk (00:33:53) Time Perception, Tool: Space-Time Bridging Meditation; Chimps, Vastness (00:42:13) Sponsor: AG1 (00:43:37) Consciousness, Collective Experiences & Brain Synchronization (00:50:04) Music, Concerts & Awe; Sparring, Transcendence (01:01:28) Joe Strummer (01:06:04) Inhibitors of Awe, Self-Focus & Narcissism (01:12:41) Sponsor: Function (01:13:52) Sports, Collective Effervescence (01:19:03) Social Media & Online Life, Social Community (01:29:51) Designing Cities & Places for Awe (01:34:29) Sponsor: Our Place (01:35:44) Embarrassment, Teasing; Collective Values (01:43:05) Male Friendship, Teasing (01:47:50) Isolation, Loneliness, Reemergence of Community (01:54:33) Psychedelics, Awe, Treating Trauma; Microdosing (02:01:18) Looking Forward, Awe Design (02:08:36) Campfires, Connection, Red Light (02:13:34) Life After Death; Acknowledgments (02:17:19) Zero-Cost Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Sponsors, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices
In this special partnered episode of the BloodStream Podcast, hosts Patrick James Lynch and Amy Board speak with hematologist Dr. Tami Singleton about hemophilia A and B with inhibitors, a complex condition that changes how bleeding episodes are treated. Dr. Singleton explains what inhibitors are, why they develop, and how they impact clotting and everyday life for patients and families. The conversation also explores SEVENFACT, a recombinant factor VIIa bypassing agent, including how it works and what patients should know about dosing and treatment planning. Click here to learn more about SEVENFACT.
Feline diabetes management is evolving fast, and SGLT2 inhibitors are at the center of that conversation. In this deep-dive episode, Dr. Susan and Dr. Jolle are joined by Dr. Renee Rucinsky — board-certified feline specialist, owner of Mid Atlantic Cat Hospital and Mid Atlantic Feline Thyroid Center, and a key contributor to the AAHA diabetes management guidelines, including the upcoming updated edition. Dr. Rucinsky walks through the mechanism of action of oral SGLT2 inhibitors, their emerging role in feline diabetes management, patient selection criteria, and what the latest evidence is telling us about when and how to use them in practice. If you've been fielding questions from clients about these drugs — or wondering where they fit in your own protocols — this episode gives you the clinical clarity to move forward with confidence.Thanks for tuning in to the Purr Podcast with Dr. Susan and Dr. Jolle!If you enjoyed today's episode, don't forget to subscribe, rate, and leave us a review—it really helps other cat lovers and vet nerds find the show. Follow us on social media for behind-the-scenes stories, cat trivia, and the occasional bad pun. And remember: every day is better with cats, curiosity, and maybe just a little purring in the background. Until next time—stay curious, stay kind, and give your cats an extra chin scratch from us. The Purr Podcast – where feline medicine meets feline fun.
Anesthesia and Critical Care Reviews and Commentary (ACCRAC) Podcast
In this 329th episode I welcome Dr. Tyler Jones, founder of the Anesthesia Thoughts Blog, to the show to discuss management of SGLT2 inhibitors and GLP1 receptor agonists. We discuss the evidence for and against holding them before surgery and what you need to know to manage patients on them.Our Sponsors:* Check out BetterHelp: https://www.betterhelp.com* Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com* Check out Factor: https://factormeals.com/accrac50off* Check out Quince: https://quince.com/ACCRAC* Check out Truelearn and use my code ACCRAC for a great deal: https://Truelearn.comAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
Real Life Pharmacology - Pharmacology Education for Health Care Professionals
P2Y12 inhibitors are a cornerstone of antiplatelet therapy in cardiovascular disease. These agents block the P2Y12 receptor on platelets, preventing ADP-mediated activation and reducing platelet aggregation. By inhibiting this amplification pathway, they help prevent arterial thrombosis in conditions such as acute coronary syndrome, percutaneous coronary intervention, stroke, and peripheral artery disease. The most commonly used oral agents include clopidogrel, prasugrel, and ticagrelor, each with important pharmacokinetic and clinical differences that influence agent selection. From a pharmacist's perspective, choosing the right P2Y12 inhibitor requires balancing ischemic benefit with bleeding risk. Clopidogrel requires CYP2C19 activation and is subject to drug interactions and genetic variability. Prasugrel provides more potent inhibition but carries a higher bleeding risk and is contraindicated in patients with prior stroke or TIA. Ticagrelor offers reversible inhibition but comes with unique considerations such as dyspnea and drug interactions via CYP3A4. Understanding these nuances allows pharmacists to optimize dual antiplatelet therapy and improve patient outcomes. Be sure to check out our free Top 200 study guide – a 31 page PDF that is yours for FREE! Support The Podcast and Check Out These Amazing Resources! NAPLEX Study Materials BCPS Study Materials BCACP Study Materials BCGP Study Materials BCMTMS Study Materials Meded101 Guide to Nursing Pharmacology (Amazon Highly Rated) Guide to Drug Food Interactions (Amazon Best Seller) Pharmacy Technician Study Guide by Meded101
© 2020-2026 Ivy Podcast Discovery LLC
